Ifinatamab Deruxtecan Biologics License Application For Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

By Reuters News

- Merck & Co Inc MRK.N:

  • IFINATAMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR CERTAIN PATIENTS WITH PREVIOUSLY TREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN

  • MERCK & CO - WITHDRAWAL BASED ON FDA DISCUSSIONS; PHASE 2 DATA DO NOT SATISFY APPROVAL REQUIREMENTS

  • MERCK & CO - PATIENT ENROLLMENT CONTINUES IN IDEATE-LUNG02 PHASE 3 TRIAL FOR IFINATAMAB DERUXTECAN

  • MERCK & CO - TWO ADDITIONAL PHASE 3 TRIALS UNDERWAY FOR IFINATAMAB DERUXTECAN IN CRPC AND ESCC

  • MERCK & CO - DAIICHI SANKYO AND MERCK WITHDRAW BLA FOR IFINATAMAB DERUXTECAN IN ES-SCLC IN U.S.

Further company coverage: MRK.N

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk